- Home
- INTS vs PIII Comparison
INTS vs PIII Comparison
Compare INTS & PIII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTS
- PIII
- Stock Information
- Founded
- INTS 2012
- PIII 2015
- Country
- INTS United States
- PIII United States
- Employees
- INTS N/A
- PIII N/A
- Industry
- INTS Biotechnology: Pharmaceutical Preparations
- PIII Medical/Nursing Services
- Sector
- INTS Health Care
- PIII Health Care
- Exchange
- INTS Nasdaq
- PIII Nasdaq
- Market Cap
- INTS 7.4M
- PIII 21.4M
- IPO Year
- INTS 2023
- PIII N/A
- Fundamental
- Price
- INTS $0.33
- PIII $6.32
- Analyst Decision
- INTS Strong Buy
- PIII Buy
- Analyst Count
- INTS 3
- PIII 2
- Target Price
- INTS $8.50
- PIII $16.25
- AVG Volume (30 Days)
- INTS 3.3M
- PIII 3.7K
- Earning Date
- INTS 08-07-2025
- PIII 08-06-2025
- Dividend Yield
- INTS N/A
- PIII N/A
- EPS Growth
- INTS N/A
- PIII N/A
- EPS
- INTS N/A
- PIII N/A
- Revenue
- INTS N/A
- PIII $1,485,192,000.00
- Revenue This Year
- INTS N/A
- PIII N/A
- Revenue Next Year
- INTS N/A
- PIII $7.92
- P/E Ratio
- INTS N/A
- PIII N/A
- Revenue Growth
- INTS N/A
- PIII 9.79
- 52 Week Low
- INTS $0.26
- PIII $6.00
- 52 Week High
- INTS $5.09
- PIII $32.54
- Technical
- Relative Strength Index (RSI)
- INTS 41.29
- PIII 42.33
- Support Level
- INTS $0.26
- PIII $6.00
- Resistance Level
- INTS $0.32
- PIII $6.46
- Average True Range (ATR)
- INTS 0.03
- PIII 0.21
- MACD
- INTS 0.02
- PIII 0.07
- Stochastic Oscillator
- INTS 62.56
- PIII 33.33
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.
About PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.